Navigation Links
For the First Time, a Glioma ¨C Brain Cancer ¨C may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing
Date:12/17/2009

BEIJING, Dec. 17 /PRNewswire-Asia/ -- Using a novel stem cell based technology of Cellonis Biotechnologies, Beijing, a Chinese research/medical team may eliminate a glioma -- brain cancer -- of a 36 year old Norwegian patient in a hospital in Beijing. The treatment shows that the activated immune system can directly kill tumor stem cells as well as cancer daughter cells. The amazing outcome of this novel treatment within a Comprehensive Cancer Therapy tells Cellonis that the future vaccination therapies may be targeted towards cancer stem cell lysates to improve the antigen-presenting Dendritic Cell response.

(Photo: http://www.newscom.com/cgi-bin/prnh/20091217/CNTH007)

Arve Johnsen, 36, from Norway, a patient diagnosed with glioma in 2006 and relapsed in 2009 after surgical resection. He arrived in Beijing in August 2009 with his wife Vanja and a one-year-old daughter, with the hope that the doctors in Norway were wrong. They told the family there is no other option anymore in the Scandinavian countries or in Europe for Arve to control the progress of disease and prolong his life. Driven by the hope that their daughter could grow up with a father, the Johnsen family started a research campaign to find other treatments worldwide, to give Arve a new hope.

Comprehensive Cancer Therapy in China

The Johnsen's, having heard about the sustainable success of a Comprehensive Cancer Therapy (CCT) in China, decided to try for this last chance in a country 10,000 km away from Norway. This kind of CCT had been developed in the past few years by a Chinese team of scientific researchers and clinical doctors in Beijing, combining conventional canc
'/>"/>

SOURCE Cellonis Biotechnologies
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
3. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
4. Genmab Announces 2007 First Half Year Results
5. Pharsight Achieves First License Sale for Public-Source Database
6. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. China Medical Technologies Reports First Quarter Financial Results
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014  AtheroNova Inc. (OTCBB: AHRO), a ... of compounds to safely regress atherosclerotic plaque and ... its partner, CardioNova, has accomplished first dosing of ... AtheroNova,s lead compound, AHRO-001.  This Phase 1b trial ... 1 safety trial completed in February 2014, in ...
(Date:7/30/2014)... Hartford, CT (PRWEB) July 30, 2014 ... economic development organization based in East Hartford, Conn., was ... on Phase II of a project that will determine ... facility in rural north-central Connecticut. USDA Rural Development provided ... (RBEG) program for the second phase of the feasibility ...
(Date:7/30/2014)... 2014 Immunology Summit-2014 ... Principle Investigators, scientists in the field, which includes ... at Case Western Reserve University School of Medicine, ... on “The effects of recombinant human IL-6 ... metalloproteinase-9”. Arya Biragyn, a Senior investigator at National ...
(Date:7/29/2014)... 2014 “PharmaSphere: Emerging Biotech Investment ... Capital Funding” report provides in-depth analysis of the ... and venture capital segments of the financial industry, ... have significant impact on the future of emerging ... the report identifies regions of the world that ...
Breaking Biology Technology:AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 2USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 3Unveiling Breakthroughs in Clinical & Cellular Immunology 2Unveiling Breakthroughs in Clinical & Cellular Immunology 3Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 2Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 3Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 4
... KALAMAZOO, Mich., Oct. 28 Stryker Corporation (NYSE: SYK ... District of Massachusetts has returned an indictment charging Stryker Biotech ... with wire fraud, conspiracy to defraud the U.S. Food and ... statements to the FDA. The Company disclosed in March of ...
... INCLINE VILLAGE, Nev., Oct. 28 PDL BioPharma, Inc. ... has priced a $300 million securitization transaction intended to ... , Upon closing of the transaction, which is expected ... sell to QHP Royalty Sub LLC ("QHP"), a newly-formed ...
... , GAITHERSBURG, Md., Oct. 28 GenVec, Inc. (Nasdaq: ... the third quarter ended September 30, 2009 on Thursday, November ... call at 10:00 a.m. EST on Friday, November 6, 2009 ... http://www.newscom.com/cgi-bin/prnh/20081205/DC50112LOGO ) , To listen to ...
Cached Biology Technology:Stryker Statement in Response to the Indictment of Its Biotech Division 2PDL BioPharma Announces Pricing of $300,000,000 Securitization Transaction 2PDL BioPharma Announces Pricing of $300,000,000 Securitization Transaction 3GenVec Announces Third Quarter 2009 Results Conference Call 2
(Date:7/30/2014)... pledge of $1 million from the Cornelia Cogswell Rossi ... Biometry Center. , The newly established Connie ... to develop a greater breadth and depth of knowledge ... the pace of research to improve human health. , ... for the Laboratory and its external partners, supporting research ...
(Date:7/30/2014)... July 30, 2014 ResearchMoz ... Government Biometric Systems Market 2014-2024   Business Strategies, Industry ... Biometric Systems Market 2014-2024" offers the reader detailed ... the next ten years, alongside potential market opportunities ... forecasts. To view the table of ...
(Date:7/30/2014)... across-the-board increase in Impact Factors for its molecular ... Reports (Thomson Reuters, 2014) show that Clinical ... in Biochemistry , Biochemical Society Transactions ... in their Impact Factors. The journals are owned ... Press Limited. , 2014 Impact Factors (2013 Impact ...
Breaking Biology News(10 mins):Rossi Foundation pledges $1M for JAX neurobehavioral research center 2Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 2Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 3Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 4Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 5Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 6Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 7Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 8Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 9Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 10Across-the-board Impact Factor increases for Portland Press Limited 2
... / b3c newswire / - Kinaxo Biotechnologies GmbH has ... identify the protein kinase mTOR as a new ... a non-steroidal, anti-inflammatory Cox-2 inhibitor approved for the ... In addition, celecoxib’s anti-proliferative effect has earned it ...
... of memories for a lifetime. But when our eyes ... also creates temporary memories that help us process complex ... For decades, scientists have held that such short-term memories ... the course of several seconds. Now researchers at ...
... of healthy people can cause serious infections in premature ... university Karolinska Institutet have now found an explanation for ... to the skin and quickly develop dynamic ecosystems: the ... establishes itself on the child,s skin and mucous ...
Cached Biology News:KINAXOs Cellular Target Profiling reveals mTOR as a new target of Celebrex 2Some short-term memories die suddenly, no fading 2Tufted bacteria cause infection in premature babies 2
Peroxidase Protective Buffer is a diluent formulated to stabilize the activity of Chemicon horseradish peroxidase (HRP)-antibody conjugates at high conjugate dilution for extended periods....
... Digest Medium (TSB), USP is a highly ... general laboratory use. Due to the inclusion ... medium will support growth of many fastidious ... , Product conforms to United States Pharmacopeia ...
... and endothelial cells-directed transfection reagent ... peptide-conjugated polyethylenimine which allows targeted ... and endothelial cells. Integrins are ... and cell-matrix adhesion processes. Many ...
... is used to predict the ... sequence up to 3,200 bases, ... of primers and GC clamps ... gradient gel electrophoresis (DGGE), constant ...
Biology Products: